Zurich Cantonal Bank
TSHA icon

Zurich Cantonal Bank’s Taysha Gene Therapies TSHA Stock Holding History

Zurich Cantonal Bank’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Sell
49,213
-31,566
-39% -$187K ﹤0.01% 2140
2026
Q1 		$361K Buy
80,779
+13,302
+20% +$61.9K ﹤0.01% 2003
2025
Q4 		$371K Buy
+67,477
New +$328K ﹤0.01% 1943

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zurich Cantonal Bank's TSHA Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Taysha Gene Therapies (TSHA) stake by 39% in Q2 2026, selling an estimated $187K and leaving 49,213 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

Zurich Cantonal Bank first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. The position peaked at $371K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Zurich Cantonal Bank held 49,213 shares of Taysha Gene Therapies worth $335K as of Q2 2026.
  • Zurich Cantonal Bank sold 31,566 Taysha Gene Therapies shares in Q2 2026, an estimated $187K.
  • Taysha Gene Therapies made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2140 holding.
  • Zurich Cantonal Bank first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • Zurich Cantonal Bank's Taysha Gene Therapies position peaked at $371K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.